HomeComparePSCBF vs SPHD

PSCBF vs SPHD: Dividend Comparison 2026

PSCBF yields 1818.18% · SPHD yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.81M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
SPHD
SPHD
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full SPHD calculator →

Portfolio growth — PSCBF vs SPHD

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSCBF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,442,181.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + SPHD for your $10,000?

PSCBF: 50%SPHD: 50%
100% SPHD50/50100% PSCBF
Portfolio after 10yr
$2051707341.93M
Annual income
$1,851,398,394,378,653.00/yr
Blended yield
90.24%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
SPHD buys
0
No recent congressional trades found for PSCBF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFSPHD
Forward yield1818.18%4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$4103414683.84M$28.0K
Annual income after 10y$3,702,796,788,756,407.00$899.19
Total dividends collected$4074760433.31M$6.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PSCBF vs SPHD ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$192,518$181,818.18$11,120$420.00+$181.4KPSCBF
2$3,477,331$3,271,336.99$12,357$458.31+$3.46MPSCBF
3$58,943,217$55,222,471.89$13,721$499.76+$58.93MPSCBF
4$937,891,469$874,822,227.57$15,227$544.58+$937.88MPSCBF
5$14,012,869,532$13,009,325,660.38$16,885$593.02+$14012.85MPSCBF
6$196,647,994,247$181,654,223,846.76$18,713$645.34+$196647.98MPSCBF
7$2,592,865,386,485$2,382,452,032,641.56$20,724$701.81+$2592865.37MPSCBF
8$32,132,661,421,271$29,358,295,457,731.54$22,938$762.73+$32132661.40MPSCBF
9$374,409,247,740,494$340,027,300,019,734.44$25,372$828.41+$374409247.72MPSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$28,047$899.19+$4103414683.81MPSCBF

PSCBF vs SPHD: Complete Analysis 2026

PSCBFStock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

SPHDETF

SPHD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in SPHD shares.

Full SPHD Calculator →
📬

Get this PSCBF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.